148 related articles for article (PubMed ID: 38290786)
1. European priority review vouchers for neglected disease product development.
Ridley DB; Lasanta AM; Storer Jones F; Ridley SK
BMJ Glob Health; 2024 Jan; 9(1):. PubMed ID: 38290786
[TBL] [Abstract][Full Text] [Related]
2. The Commercial Market For Priority Review Vouchers.
Ridley DB; Régnier SA
Health Aff (Millwood); 2016 May; 35(5):776-83. PubMed ID: 27140982
[TBL] [Abstract][Full Text] [Related]
3. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.
Ridley DB; Sánchez AC
Lancet; 2010 Sep; 376(9744):922-7. PubMed ID: 20833303
[TBL] [Abstract][Full Text] [Related]
4. Priorities for the Priority Review Voucher.
Ridley DB
Am J Trop Med Hyg; 2017 Jan; 96(1):14-15. PubMed ID: 27573624
[TBL] [Abstract][Full Text] [Related]
5. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
[TBL] [Abstract][Full Text] [Related]
6. Preserving an Incentive for Global Health R&D: The Priority Review Voucher Secondary Market.
Robertson AS
Am J Law Med; 2016 May; 42(2-3):524-542. PubMed ID: 29086641
[TBL] [Abstract][Full Text] [Related]
7. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
8. Addition of generic medication vouchers to a pharmacist academic detailing program: effects on the generic dispensing ratio in a physician-hospital organization.
Bhargava V; Greg ME; Shields MC
J Manag Care Pharm; 2010; 16(6):384-92. PubMed ID: 20635829
[TBL] [Abstract][Full Text] [Related]
9. Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective.
Tafuri G; Bracco A; Grueger J
Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):381-389. PubMed ID: 34930086
[TBL] [Abstract][Full Text] [Related]
10. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
11. Evaluation of the Healthy Start voucher scheme on maternal vitamin use and child breastfeeding: a natural experiment using data linkage.
Dundas R; Boroujerdi M; Browne S; Deidda M; Bradshaw P; Craig P; McIntosh E; Parkes A; Wight D; Wright C; Leyland AH
Public Health Res (Southampt); 2023 Nov; 11(11):1-101. PubMed ID: 37953640
[TBL] [Abstract][Full Text] [Related]
12. The Tropical Disease Priority Review Voucher: A Game-Changer for Tropical Disease Products.
Berman J; Radhakrishna T
Am J Trop Med Hyg; 2017 Jan; 96(1):11-13. PubMed ID: 27573627
[TBL] [Abstract][Full Text] [Related]
13. Can vouchers make a difference to the use of private primary care services by older people? Experience from the healthcare reform programme in Hong Kong.
Yam CH; Liu S; Huang OH; Yeoh EK; Griffiths SM
BMC Health Serv Res; 2011 Oct; 11():255. PubMed ID: 21978140
[TBL] [Abstract][Full Text] [Related]
14. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
15. A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.
da Costa Gonçalves F; Demirci E; Zwiers A
Clin Transl Sci; 2022 Aug; 15(8):1959-1967. PubMed ID: 35561071
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries.
Atikeler EK; Özçelikay G
Springerplus; 2016; 5(1):1876. PubMed ID: 27833835
[TBL] [Abstract][Full Text] [Related]
17. A taxonomy and results from a comprehensive review of 28 maternal health voucher programmes.
Bellows BW; Conlon CM; Higgs ES; Townsend JW; Nahed MG; Cavanaugh K; Grainger CG; Okal J; Gorter AC
J Health Popul Nutr; 2013 Dec; 31(4 Suppl 2):106-28. PubMed ID: 24992806
[TBL] [Abstract][Full Text] [Related]
18. Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU.
Demirci E; Omes-Smit G; Zwiers A
Clin Transl Sci; 2023 Jul; 16(7):1127-1133. PubMed ID: 37013379
[TBL] [Abstract][Full Text] [Related]
19. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of a competitive voucher scheme to reduce sexually transmitted infections in high-risk groups in Nicaragua.
Borghi J; Gorter A; Sandiford P; Segura Z
Health Policy Plan; 2005 Jul; 20(4):222-31. PubMed ID: 15965034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
